News Column

Studies from P. von Breitenbuch and Co-Researchers Update Current Data on Immunoglobulins

June 4, 2014



By a News Reporter-Staff News Editor at Biotech Week -- A new study on Immunology is now available. According to news reporting originating in Regensburg, Germany, by NewsRx journalists, research stated, "CD22 is a cell surface glycoprotein restricted to normal and malignant B-cells and is the target of several anti-CD22 antibody-based cancer therapies. For therapeutic antibody-payload conjugates, it is important to understand the subcellular trafficking of anti-CD22 antibodies to optimize antibody and/or linker-drug properties to maximize antitumor efficacy."

The news reporters obtained a quote from the research, "It is agreed that anti-CD22 antibodies rapidly internalize, but controversial whether they recycle or are degraded in lysosomes, and it is unclear if trafficking is antibody or cell-type dependent. No studies examined anti-CD22 trafficking to either pathway in B-cells over time by dual immunofluorescence microscopy, likely partly because multiple samples of suspension cells are tedious to stain. We overcame this by using DropArray , a novel wall-less 96-well plate technology allowing rapid simultaneous staining of suspension or adherent cells in small (10-20 mu L) volumes. We examined the time-course of trafficking of five different anti-CD22 antibodies in eight B-cell lines representing four B-cell cancer types and show that in all cases antibodies internalize within 5 min and recycle, with only small amounts eventually trafficking to lysosomes. CD22 also localizes to recycling endosomes at steady state in the absence of antibody."

According to the news reporters, the research concluded: "Our data may help explain the differential efficacies of anti-CD22 antibodies conjugated to different therapeutic payloads."

For more information on this research see: DropArray , a Wall-Less 96-Well Plate for Uptake and Immunofluorescence Microscopy, Confirms CD22 Recycles. Surgical Innovation, 2014;21(2):187-193. Surgical Innovation can be contacted at: Sage Publications Inc, 2455 Teller Rd, Thousand Oaks, CA 91320, USA. (Sage Publications - www.sagepub.com/; Surgical Innovation - sri.sagepub.com)

Our news correspondents report that additional information may be obtained by contacting P. von Breitenbuch, Krankenhaus Barmherzigen Bruder, Regensburg, Germany. Additional authors for this research include T. Jeiter, S. Schreml, G. Glockzin, A. Agha, P. Piso and H.J. Schlitt (see also Immunology).

Keywords for this news article include: Antibodies, Europe, Germany, Regensburg, Immunology, Blood Proteins, Immunoglobulins, Immunofluorescence

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters